Key result
Late STEMI presentation shows no independent link to increased 3-year mortality versus early presentation.
Why the study?
Real-world data on baseline characteristics, clinical practice, and outcomes of late presentation (12 to 48 h of symptom onset) in STEMI patients are limited.
Does late presentation (12 to 48 h) compared to early presentation (<12 h) worsen 180-day and 3-year all-cause mortality in patients with STEMI?
Cohort (n=5,826)
Yes
Does late presentation (12 to 48 h) compared to early presentation (<12 h) worsen 180-day and 3-year all-cause mortality in patients with STEMI?
Absolute Event Rate: 16.2% vs 10.6%
p-value: p=<0.001
Late presentation of STEMI (12-48 hours) is associated with a steep decline in the use of primary PCI and higher unadjusted mortality rates compared to early presentation.
Higher unadjusted mortality in late STEMI presenters did not persist after adjustment; leaves open whether delay independently affects prognosis.
BACKGROUND Real-world data on baseline characteristics, clinical practice, and outcomes of late presentation (12 to 48 h of symptom onset) in patients with ST-segment elevation myocardial infarction (STEMI) are limited. OBJECTIVES This study aimed to investigate real-world features of STEMI late presenters in the contemporary percutaneous coronary intervention (PCI) era. METHODS Of 13,707 patients from the Korea Acute Myocardial Infarction Registry-National Institutes of Health database, 5,826 consecutive patients diagnosed with STEMI within 48 h of symptom onset during 2011 to 2015 were categorized as late (12 to 48 h; n = 624) or early (<12 h; n = 5,202) presenters. Coprimary outcomes were 180-day and 3-year all-cause mortality. RESULTS Late presenters had remarkably worse clinical outcomes than early presenters (180-day mortality: 10.7% vs. 6.8%; 3-year mortality: 16.2% vs. 10.6%; both log-rank p < 0.001), whereas presentation at ≥12 h of symptom onset was not independently associated with increased mortality after STEMI. The use of invasive interventional procedures abruptly decreased from the first (<12 h) to the second (12 to 24 h) 12-h interval of symptom-to-door time ("no primary PCI strategy" increased from 4.9% to 12.4%, and "no PCI" from 2.3% to 6.6%; both p < 0.001). Mortality rates abruptly increased from the first to the second 12-h interval of symptom-to-door time (from 6.8% to 11.2% for 180-day mortality; from 10.6% to 17.3% for 3-year mortality; all p < 0.05). CONCLUSIONS Data from a nationwide prospective Korean registry reveal that inverse steep differences in the use of invasive interventional procedures and mortality rates were found between early and late presenters after STEMI. A multidisciplinary approach is required in identifying late presenters of STEMI who can benefit from invasive interventional procedures until further studied.
No takes yet. Share an insight, caveat, or question.
Cho et al. (2021) conducted a cohort in ST-segment elevation myocardial infarction (STEMI) (n=5,826). Late presentation (12 to 48 h of symptom onset) vs. Early presentation (<12 h of symptom onset) was evaluated on 180-day and 3-year all-cause mortality (p=<0.001). Late presentation (12-48 h) in STEMI patients had higher unadjusted 3-year mortality than early presentation (16.2% vs 10.6%, p<0.001), but was not independently associated with increased mortality.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: